Program Overview
Time | Program |
02:00 PM - 04:00 PM |
Pre-Conference | Workshop by BiologixFerriprox® in the Management of Iron Overload
Pre-Conference | Workshop by BiologixChairperson : Fatheya Al KhajaUnited Arab EmiratesTopics : UK experience in Beta Thalassemia Iron Overload Management
Paul TelferUnited Kingdom 02:00 PM - 02:40 PM
UAE experience in the management of severe iron overload (DFP monotherapy vs Combination) & Discussion
Hani DwedarUnited Arab Emirates 02:40 PM - 03:00 PM
Adult Case Presentation & Discussion
![]() Hazzaa Al ZahraniSaudi Arabia 03:00 PM - 03:20 PM
Pediatric Case Presentation & Discussion
Yasser WaliOman 03:20 PM - 03:40 PM
Adult Case Presentation & Discussion
Amar LalUnited Arab Emirates 03:40 PM - 04:00 PM
|
04:00 PM - 04:25 PM | Industry Symposium by Novo NordiskN8-GP (turoctocog alfa pegol; Esperoct): An extended half-life recombinant factor VIII molecule for patients with haemophilia A |
04:30 PM - 04:55 PM | Industry Symposium by MSDAntifungal prophylaxis in high-risk patients with hematological malignancies |
05:00 PM - 05:25 PM | Industry Symposium by RocheDLBCL: Where do we stand in 2022? |
05:30 PM - 06:25 PM | Industry Symposium by NovartisASH Updates in SCD & Cardiovascular Risk in PV |
06:30 PM - 06:55 PM | Industry Symposium by BMS 1Management of transfusion-dependent thalassemia: Unmet needs and novel therapies |
07:00 PM - 07:25 PM | Industry Symposium by SandozBiosimilars for treating lymphoma : Rixathon “Rituximab Biosimilar by Sandoz” |
07:30 PM - 07:55 PM | Industry Symposium by SanofiThe Era of MRD Negativity and it’s impact on MM Management & Isatuximab phase 3 pivotal clinical Trial IKEMA trial |
08:00 PM - 08:25 PM | Industry Symposium by AstraZenecaHow to Select BTKI for your Patient?... The luxury to choose |
08:30 PM - 08:55 PM | Industry Symposium by BMS 2TDT.. What has changed? |
Time | Program |
02:00 PM - 02:25 PM | Industry Symposium by Eli LillyIndolent lymphoproliferative disease |
02:30 PM - 02:55 PM | Industry Symposium by AstellasADMIRAL Study: The paradigm shift for R/R FLT3 mutated AML Patients |
02:55 PM - 03:00 PM | Opening Remarks |
03:00 PM - 04:20 PM |
Session 1: Myeloid Disorders
Session 1: Myeloid DisordersChairperson : Salam Al KindiOmanMahmoud MarashiUnited Arab EmiratesMurtadha Al-KhaboriOmanTopics : Management of PV in 2022
Ayalew TefferiUnited States 03:00 PM - 03:20 PM
Diagnosis and Prognosis of AML in 2022
Michael SavonaUnited States 03:20 PM - 03:40 PM
Diagnosis, Prognosis and management of MDS including MDS-MPN
Ayalew TefferiUnited States 03:40 PM - 04:00 PM
Treatment of AML in 2022, moving forward from 7+3
Michael SavonaUnited States 04:00 PM - 04:20 PM
|
04:25 PM - 04:40 PM | ALL Case Presentations |
04:45 PM - 05:25 PM |
Q&A - Meet the Experts (Day 1)
Q&A - Meet the Experts (Day 1)Chairperson : Salam Al KindiOmanMurtadha Al-KhaboriOmanMahmoud MarashiUnited Arab EmiratesTopics : Q&A - Meet the Experts
Ayalew TefferiUnited States 07:10 PM - 07:50 PM
Q&A - Meet the Experts
Michael SavonaUnited States 07:10 PM - 07:50 PM
Q&A - Meet the Experts
Amar LalUnited Arab Emirates 04:45 PM - 05:25 PM
|
05:30 PM - 05:55 PM | Industry Symposium by StemlineBlastic Plasmacytoid Dendritic Cell Neoplasm BPDCN (Disease state, History, Diagnosis and Novel therapies) |
05:55 PM - 06:20 PM | Industry Symposium by Abbvie BCL2i outcomes in high-risk CLL patients |
Time | Program |
01:30 PM - 01:55 PM | Industry Symposium by MSD 2The management paradigm of cHL |
02:00 PM - 02:25 PM | Industry Symposium by Amgen Key Highlights in Managing RRMM |
02:30 PM - 02:55 PM | Industry Symposium by KyowaKirinCutaneous T-Cell Lymphomas : Overview and clinical considerations |
03:00 PM - 03:45 PM | Session 2: Best of ASH |
03:50 PM - 05:10 PM |
Session 3: Lymphoproliferative disorders I
Session 3: Lymphoproliferative disorders IChairperson : Arif AlamUnited Arab EmiratesShahrukh HashmiUnited Arab EmiratesFaraz KhanUnited Arab EmiratesTopics : How I treat Indolent lymphoma in 2022
Jeremy AbramsonUnited States 03:50 PM - 04:10 PM
Treatment of Aggressive B cell lymphoma in 2022
Jeremy AbramsonUnited States 04:10 PM - 04:30 PM
CAR T cells in lymphoma and ALL
Jeremy AbramsonUnited States 04:30 PM - 04:50 PM
How I treat CNS lymphoma in 2022
Grzegorz NowakowskiUnited States 04:50 PM - 05:10 PM
|
05:15 PM - 06:35 PM |
Session 4: Lymphoproliferative disorders II Session 4: Lymphoproliferative disorders II
Chairperson : Hassan Al YaseenUnited Arab EmiratesKayane MheidlyUnited Arab EmiratesTopics : How I treat relapsed Hodgkin lymphoma
Grzegorz NowakowskiUnited States05:15 PM - 05:35 PM
Treatment of relapsed Follicular lymphoma in 2022
Grzegorz NowakowskiUnited States05:35 PM - 05:55 PM
Diagnosis and choice of CLL therapy in 2022, How do you select?
Sameer ParikhUnited States05:55 PM - 06:15 PM
Complications of CLL and CLL therapy
Sameer ParikhUnited States06:15 PM - 06:35 PM
|
06:40 PM - 06:50 PM | Challenging Case Presentation |
06:50 PM - 07:10 PM |
Lymphoma Case Presentations
Lymphoma Case PresentationsTopics : Case Presentation 1
Amar LalUnited Arab Emirates 06:50 PM - 06:55 PM
Case Presentation
Faraz KhanUnited Arab Emirates 06:55 PM - 07:00 PM
Case Presentation 2
Amar LalUnited Arab Emirates 07:00 PM - 07:05 PM
Case Presentation
Arif AlamUnited Arab Emirates 07:05 PM - 07:10 PM
|
07:10 PM - 07:50 PM |
Q&A - Meet the Experts (Day 2)
Q&A - Meet the Experts (Day 2)Chairperson : Kayane MheidlyUnited Arab EmiratesHassan Al YaseenUnited Arab EmiratesArif AlamUnited Arab EmiratesAmar LalUnited Arab EmiratesShahrukh HashmiUnited Arab EmiratesFaraz KhanUnited Arab EmiratesTopics : Q&A - Meet the Experts
Ranjana AdvaniUnited States 06:15 PM - 06:55 PM
Q&A - Meet the Experts
Jeremy AbramsonUnited States 06:15 PM - 06:55 PM
Q&A - Meet the Experts
Grzegorz NowakowskiUnited States 06:35 PM - 07:15 PM
Q&A - Meet the Experts
Sameer ParikhUnited States 06:35 PM - 07:15 PM
|
07:55 PM - 08:20 PM | Industry Symposium by Janssen 1New Horizons in CLL management |
08:20 PM - 08:45 PM | Industry Symposium by Takeda 1Acquired Hemophilia: The Tawam Experience |
08:45 PM - 09:10 PM | Industry Symposium by Takeda 2Maximizing patients outcome in Gaucher Disease |
Time | Program |
02:00 PM - 02:25 PM | Industry Symposium by Janssen 2Advances in Management of Newly Diagnosed Multiple Myeloma |
02:30 PM - 02:55 PM | Industry Symposium by AstraZeneca 2Beyond COVID 19 Vaccination: Evusheld (tixagevimab and cilgavimab) for the Prevention of Covid-19 |
03:00 PM - 04:20 PM |
Session 5: Plasma Cell Disorders
Session 5: Plasma Cell DisordersChairperson : Ahmad AlhuraijiKuwaitMustaqeem SiddiquiUnited Arab EmiratesTopics : What are the important investigations in the new cases of myeloma and how do you follow up the case including MRD
Jesus San-MiguelSpain 03:00 PM - 03:20 PM
Is there still a role for ASCT in 2022
Morie GertzUnited States 03:20 PM - 03:40 PM
Can myeloma be cured in the era of new therapies?
Jesus San-MiguelSpain 03:40 PM - 04:00 PM
How I diagnose and treat amyloidosis in 2022
Morie GertzUnited States 04:00 PM - 04:20 PM
|
04:25 PM - 05:25 PM |
Session 6: Bleeding Disorders
Session 6: Bleeding DisordersChairperson : Amna Al MehairiUnited Arab EmiratesHadeel AmmarUnited Arab EmiratesTopics : VWD, approach to diagnosis and management
Alice MaUnited States 04:25 PM - 04:45 PM
Investigation of patients with bleeding
Alice MaUnited States 04:45 PM - 05:05 PM
Antiphospholipid syndrome, diagnosis and management
Alice MaUnited States 05:05 PM - 05:25 PM
|
05:30 PM - 05:40 PM | Myeloma Case Presentations |
05:40 PM - 06:20 PM |
Q&A - Meet the Experts (Day 3)
Q&A - Meet the Experts (Day 3)Chairperson : Amna Al MehairiUnited Arab EmiratesAhmad AlhuraijiKuwaitMustaqeem SiddiquiUnited Arab EmiratesHadeel AmmarUnited Arab EmiratesTopics : Q&A - Meet the Experts
Morie GertzUnited States 05:25 PM - 06:05 PM
Q&A - Meet the Experts
Jesus San-MiguelSpain 05:25 PM - 06:05 PM
Q&A - Meet the Experts
Alice MaUnited States 05:25 PM - 06:05 PM
Q&A - Meet the Experts
Amar LalUnited Arab Emirates 05:40 PM - 06:20 PM
|
Contact Us
Quick Links
Copyright All Rights Reserved © 2022 | Powered by Meeting Minds Experts.